MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1631721

Медицинская библиотека · Frontiers in immunology · 2025

Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.

Füll Yvonne, Schüssele Lara M, Hamza Hazem, Hoffmann Helen, Bauer Martin, Stenglein Stephan, Pötz Oliver, Steinhilber Andreas, Anselm Viktoria, Delany Mark W, Van den Brand Judith M A, Van Amerongen Geert, De Waal Leon, Pleschka Stephan, Ludwig Stephan, Planz Oliver

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

In severe COVID-19, direct-acting antiviral drugs were not effective in hyperinflammatory stages and steroid treatment may weaken host immunity. The MEK inhibitor zapnometinib, as a host-targeting drug, has demonstrated promising efficacy against severe acute viral infections. Proof-of-concept for the innovative approach was presented in a clinical Phase 2 trial with hospitalized COVID-19 patients.

METHODS

The antiviral and immunomodulatory potential of zapnometinib was investigated in samples obtained from COVID-19 patients enrolled in a Phase 2 clinical trial (RESPIRE), as well as in a SARS-CoV-2 Syrian hamster model, an acute lung injury mouse model, and in cell culture. The antiviral activity of zapnometinib was assessed using viral load reduction assays and RT-qPCR. Cytokines and chemokines were analyzed via ELISA and RT-qPCR. Alterations in T and B cells from COVID-19 patients were analyzed using flow cytometry. Biomarker analysis in hamster serum was conducted to monitor potential toxic effects.

RESULTS

Zapnometinib reduced SARS-CoV-2 viral load in hospitalized COVID-19 patients, in the hamster model and in various highly pathogenic coronaviruses in vitro. Pro-inflammatory cytokines and chemokines decreased in COVID-19 patients, in a lung injury mouse model, and in vitro in primary human blood cells treated with zapnometinib. In the hamster model, zapnometinib alleviated SARS-CoV-2-mediated lung pathology. In patients with COVID-19, zapnometinib increased T and plasma B cells.

CONCLUSION

Unlike direct-acting antivirals, zapnometinib's dual effect highlights its therapeutic potential in the treatment of severe acute viral infections, with favorable antiviral and immunomodulatory properties.

Для цитирования: Füll Yvonne, Schüssele Lara M, Hamza Hazem, Hoffmann Helen, Bauer Martin, Stenglein Stephan, Pötz Oliver, Steinhilber Andreas, Anselm Viktoria, Delany Mark W, Van den Brand Judith M A, Van Amerongen Geert, De Waal Leon, Pleschka Stephan, Ludwig Stephan, Planz Oliver. Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1631721.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.